

Complete Listing of Claims Pursuant to 37 C.F.R. §1.121

Pursuant to 37 C.F.R. §1.121 the following is a complete listing of the claims of the present application. In this set of claims, please amend the claims as follows. The following listing of claims will replace all prior versions of claims in the application:

Listing of the Claims:

1.-32. (canceled)

33. (currently amended) An isolated antibody that binds phosphorylated tau as set out in SEQ ID NO: 1, wherein the antibody binds a tau epitope comprising a serine ~~or threonine~~-residue only when the serine ~~or threonine~~ residue is phosphorylated, said serine ~~or threonine~~ residue selected from the group consisting of

- (a) ~~residue 46 in SEQ ID NO:1;~~
- (b) ~~residue 50 in SEQ ID NO:1;~~
- (c) ~~residue 52 in SEQ ID NO:1;~~
- (d) ~~residue 68 in SEQ ID NO:1;~~
- (e) ~~residue 69 in SEQ ID NO:1;~~
- (f) ~~residue 71 in SEQ ID NO:1;~~
- (g) ~~residue 111 in SEQ ID NO:1;~~
- (h) ~~residue 113 in SEQ ID NO:1;~~
- (i) ~~residue 153 in SEQ ID NO:1;~~
- (j) ~~residue 175 in SEQ ID NO:1;~~
- (k) ~~residue 182 in SEQ ID NO:1;~~
- (l) ~~residue 184 in SEQ ID NO:1;~~
- (m) ~~residue 198 in SEQ ID NO:1;~~
- (n) ~~residue 199 in SEQ ID NO:1;~~
- (o) ~~residue 202 in SEQ ID NO:1;~~

- (p) — residue 205 in SEQ ID NO:1;
- (q) — residue 208 in SEQ ID NO:1;
- (r) — residue 210 in SEQ ID NO:1;
- (s) — residue 212 in SEQ ID NO:1;
- (t) — residue 214 in SEQ ID NO:1;
- (u) — residue 217 in SEQ ID NO:1;
- (v) — residue 220 in SEQ ID NO:1;
- (w) — residue 231 in SEQ ID NO:1;
- (x) — residue 235 in SEQ ID NO:1;
- (y) — residue 237 in SEQ ID NO:1;
- (z) — residue 238 in SEQ ID NO:1;
- (aa) — residue 262 in SEQ ID NO:1;
- (bb) — residue 263 in SEQ ID NO:1;
- (cc) — residue 293 in SEQ ID NO:1;
- (dd) — residue 324 in SEQ ID NO:1;
- (ee) — residue 356 in SEQ ID NO:1;
- (ff) — residue 361 in SEQ ID NO:1;
- (gg) — residue 400 in SEQ ID NO:1;
- (hh) — residue 403 in SEQ ID NO:1;
- (ii) — residue 404 in SEQ ID NO:1; and
- (jj) — residue 422 in SEQ ID NO:1.

34. (canceled)

35. (canceled)

36. (previously presented) The antibody of claim 33, wherein the antibody is a F_{ab} fragment.

37. (previously presented) The antibody of claim 33, wherein the antibody is a monoclonal antibody.

38. (previously presented) A hybridoma that produces an antibody of claim 37.

39. (previously presented) A method of detecting a phosphorylated tau protein as set out in SEQ ID NO: 1 comprising

(a) contacting a sample comprising a tau protein with an antibody that binds phosphorylated tau according to claim 33; and

(b) detecting binding of the antibody to phosphorylated tau protein.

40.-66. (canceled)